Inclusion Criteria:

• Male or female

• Histologically proven, resected lung cancer of the following histologic types:

  • squamous cell carcinoma;
  • adenocarcinoma;
  • undifferentiated large cell carcinoma;
  • non-small cell; and
  • not otherwise specified.
• Age equal to or greater than 18 years
• American Joint Committee (AJC) Stage I-III disease (if all detectable tumours can be encompassed by radiation therapy fields, including both the primary tumour and the involved lymph nodes); patients with positive supraclavicular nodes (N3) are not eligible
• Able and willing to follow instructions and comply with the protocol
• Provide written informed consent prior to participation in this study
• Karnofsky Performance Scale score equal to or greater than 70
• Measurable disease on the CT and PET images
• Patient must be deemed eligible for the radical combined-modality therapy.

Exclusion Criteria:

• Nursing or pregnant females
• MI disease
• N3 disease (patients with positive supraclavicular nodes are not eligible)
• Karnofsky performance status less than 70
• Patients who have undergone complete tumour resection
• Patients with post-resection intrathoracic tumour recurrence
• Evidence of small cell history
• Age less than 18 years
• Prior or concurrent malignancy except non-melanomatous skin cancer (unless disease free for at least 5 years)
• Prior radiotherapy to the thorax or neck
• Prior chemotherapy
• Patients with myocardial infarction within the preceding 6 months or symptomatic heart disease, including angina; congestive heart failure; and uncontrolled arrythmias
• Inability to maintain a state of deep inspiratory breath-hold for a minimum length of time